Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 9Thoracic 6Genitourinary 6Other solid neoplasm 2Tumor-Agnostic 1Gynecologic 1CNS 1

Conditions

HRD Cancer 1Advanced Solid Tumors 1

Interventions

pembrolizumab 14Injections 13Pemetrexed 9Specimen Handling 8Carboplatin 8tislelizumab 7Interviews as Topic 7Cisplatin 7fludarabine 5atezolizumab 5Educational Status 5Cyclophosphamide 5Standard of Care 4Practice Guidelines as Topic 4Methods 4Fluorouracil 4Early Intervention, Educational 4Capecitabine 4Biopsy 4Bevacizumab 4Trastuzumab 3Platinum 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Magnetic Resonance Spectroscopy 3Docetaxel 3Cetuximab 31,2-diaminocyclohexaneplatinum II citrate 3toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
sacituzumab govitecan × Other solid neoplasm × 30 days × Clear all
NCT04826341 2026-05-29

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
35 enrolled
Other solid neoplasmThoracic

HRD Cancer

NCT06167317 2026-05-28

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Gilead Sciences

Phase 1 Recruiting
278 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡